Personalized Medicine

Molecular pathways in cancer can be exploited for therapy, and sensitizing genetic aberrations are the ideal targets, said Alex Adjei, MD, PhD, at PMO Live 2015, the annual joint meeting of the Global Biomarkers Consortium and the World Cutaneous Malignancies Congress.
Recent advances in predictive and prognostic molecular biomarkers promise to enhance precision medicine in oncology. A rundown of the progress being made in bioinformatics, genetics, and proteomics for this purpose was delivered by several speakers at PMO Live 2015, the annual joint meeting of the Global Biomarkers Consortium and the World Cutaneous Malignancies Congress.
“I want the country that eliminated polio and mapped the human genome to lead a new era of medicine, one that delivers the right treatment at the right time.” So said the president of the United States in his State of the Union Address on January 20, 2015.
Dr. Bosserman explains that her practice takes a team approach to patient care. They divide the work to increase discussion with the patient and improve access and treatment. This is crucial to the care process but is sometimes difficult for patients to understand.
Recent advances in molecular technologies have enabled the dissection of inhibitory pathways within tumors and identification of inflammatory signals within the tumor microenvironment that regulate host immune responses.
Two orally available experimental drugs achieved response in patients with BRCA-deficient solid tumors in a phase 1 study of 38 patients.
About 3% to 5% of the general population is believed to have a mutation in the gene that encodes a major 5-fluorouracil (5-FU) metabolizing enzyme.
About 3% to 5% of the general population is believed to have a mutation in the gene that encodes a major 5-fluorouracil (5-FU) metabolizing enzyme.

In catching up with breast cancer and several hematologic malignancies, non–small cell lung cancer (NSCLC) has made recent advances in targeting genomic mutations that will provide us with the ability to offer more targeted treatment options.

The shift from dose-intense standard chemotherapy to therapies targeting specific signaling pathways, molecular targets, or elements of the tumor microenvironment presents a number of challenges to the oncology professional and the patient.


Results 1 - 10 of 10